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Key questions
What is already known about this subject?
 ► The use of social networks, especially Twitter, has 
become common for sharing and spreading sci-
entific information, including in oncology. For the 
possibility to deliver effective short messages and 
join online discussions, Twitter has removed some 
traditional barriers in the communication between 
key stakeholders in oncology, enhancing the use of 
this channel as preferential during medical events
What does this study add?
 ► The analysis of the communication and interaction 
flows during ESMO 2018 meeting confirmed Twitter 
to be a common platform of live data sharing during 
the one major oncology meeting. Intense participa-
tion of commercial and non- commercial users has 
been reported, showing that Twitter may serve as an 
effective channel for pharmaceutical companies and 
biotech investors. However, the main users had for 
non- commercial purposes, intended to share news 
in oncology for a variegated audience.
How might this impact on clinical practice?
 ► Despite commercial users are generally identifiable 
on Twitter, the absence of a clear disclosure of po-
tential conflict of interests (COIs) of non- commer-
cial users may represent an aspect deserving more 
transparency. Safe and high- quality tweeting during 
oncology meetings calls all the relevant stakehold-
ers to action, committing for transparency. Our pro-
posal is to disclose relevant COIs when elsewhere 
provided, such as in peer- reviewed publications, to 
ensure consistency across the different sources and 
appropriately inform who access the tweets.
AbstrAct
Background Twitter is a microblogging service providing 
a platform for social networking. For medical information, 
Twitter is an interesting channel for sharing and spreading 
information and as an engagement platform for different 
stakeholders. Benefits and caveats of uncontrolled medical 
information must be carefully pondered, considering the 
possible intended and unintended adverse outcomes of 
uncontrolled influencing. The aim of this study was to 
describe the non- commercial content shared on Twitter 
and to analyse the level of influence of commercial 
tweeters during the European Society of Medical Oncology 
(ESMO) 2018 annual meeting held in Munich.
Design/methodology A retrospective analysis of 
the tweets shared in the period 19–23 October 2018 
indexed with the hashtag #ESMO18 or #ESMO2018 was 
performed; methodology of systematic reviews was 
mirrored. Commercial tweeters (pharmaceutical and 
biotechnology companies, device manufacturers and spam 
tweeters) were excluded from the primary analysis, and 
only non- commercial tweets from and about the congress 
were included. Tweets were analysed using a network 
analytical tool (NodeXL).
Results A total of 7100 tweets posted by 1334 tweeters 
were identified for the period of interest. Less than 10% 
of tweeters were identified as commercial, posting 15.7% 
of tweets and receiving almost one- quarter of retweets. 
However, pharmaceutical and biotech tweeters were 
substantially less likely to be mentioned by other tweeters. 
All of the top 10 retweeters of non- commercial content 
were clinicians and/or professional organisations, in stark 
contrast with the commercial content.
Conclusions The use of social networks in medical 
meetings, including oncology, is increasing for real- 
time communication and informed opinion- making. The 
uncontrolled spread of information on Twitter can both 
stimulate discussions on non- official and non- canonical 
channels of communication and provide uncontrolled 
influencing of diverse stakeholders. The disclosure of 
financial declarations of interest on Twitter could enhance 
the transparency of the information, as is already 
happening in medical journals.
IntRoDuCtIon
Twitter (Twitter, San Francisco, California, 
USA) is a microblogging online service estab-
lished in March 2006.1 News and updates are 
posted as tweets, which can reference other 
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users and include images and links to web pages (URLs). 
Tweets were originally restricted to 140 characters, but 
this was extended to 280 characters in November 2017. 
Brevity is key, sometimes aided by humour, although this 
can sometimes be misread as sarcasm. Users on Twitter 
can follow and be followed, but reciprocity is not manda-
tory. Users can be mentioned (or tagged) in a Tweet (@
identifier), itemising the message with an indexing word 
(#hashtag). Tweets can be replied to, liked (♥) or shared 
(retweeted) (see online supplementary file 3). The success 
of a tweet can be measured by the number of interactions, 
both likes and retweets. While Twitter is less commonly 
used by the general population than other social media 
platforms (in the USA, the figure is put at around 22% of 
the general population),2 it is the most commonly used 
social media platform at medical conferences. This might 
be partly due to the brevity of posts, and partly because it 
is an open platform without a set hierarchical structure, 
where posts are visible to all users and can be extracted 
for further study. The immediacy of tweeting means that 
individuals or professional groups can share opinions and 
exert influence over wider decision- making in a way that 
would have been unimaginable a few years ago and can 
act as a force for constructive change. New scientific and 
clinical discoveries can be shared via tweets promoting 
recent publications. However, commercial interests, 
including pharmaceutical companies and biotech 
companies, can also influence discussions and have been 
observed participating in conference tweeting. While 
commercial influence is heavily regulated by national and 
international bodies in the physical world (eg, General 
Medical Council in the UK3 and WHO internationally4) 
and is easily circumscribed in conference venues, it is less 
well understood in social media.
Aim
The purpose of this study was twofold: to describe the 
most popular non- commercial content at a major inter-
national medical oncology congress (annual European 
Society for Medical Oncology (ESMO) meeting, Munich, 
19–23 October 2018) and to analyse the level of influence 
of commercial tweeters at that conference.
MetHoDs
This was a retrospective analysis of the tweets shared at 
the annual meeting of the ESMO in the period 19–23 
October 2018, indexed with the hashtag #ESMO18 or 
#ESMO2018.
Design
Twitter data were collected retrospectively, day by day, 
between 19 and 23 October 2018 and were combined 
to produce an extract that covered the full period of the 
conference. Data from the early period of the confer-
ence, on 19 and 20 October, were shared via Twitter to 
establish a group interested in further analysis and inter-
pretation. After identifying a considerable volume of 
commercial tweeters during the early congress extracts, 
a plan was made to identify and describe the non- 
commercial tweets from and about the congress. A total 
of 7100 tweets posted by 1334 tweeters were identified for 
the period 19–23 October 2018 (inclusive). To optimise 
and enhance the data reading, the 7100 retrieved posts 
were inspected using a series of rapid inclusion and exclu-
sion criteria, as described further, to exclude commercial 
tweets from accounts promoted by pharmaceutical and 
biotech companies.
Analysis
NodeXL, a social network analytical tool, was used to 
extract tweets that included either of the congress- related 
hashtags #ESMO18 and #ESMO2018. Data about tweets, 
tweeters and retweets were extracted using methods 
described previously.5
The initial data were incomplete, with some prolific 
tweeters missing from the extract, as identified by the 
tweeters themselves. The extraction process was repeated 
until the Twitter Application Programming Interface 
provided access to the missing tweeters. In order to 
quantify the completeness of the data, the tweets posted 
using the congress hashtags were displayed in a standard 
internet browser, using the text search function in the 
browser to count the number of instances of the date (eg, 
19 Oct) in the tweets.
NodeXL produces an ‘edge’ for each tweet, retweet and 
‘mention’ of a Twitter user in a tweet. ‘Edges’ are defined 
as connections between two elements of the network. This 
information was summarised to identify Twitter accounts 
that tweeted, retweeted and/or were mentioned, using 
the URL of the individual tweets and the unique iden-
tifier of the individual retweets to remove duplicate 
content. The Twitter accounts were categorised by contri-
bution—tweeting, retweeting and/or mentioned—and 
displayed in a Venn diagram to identify accounts making 
a contribution across the different categories. Details of 
commercial tweeters identified below are blanked out.
The most popular content was identified on the basis 
of the number of retweets, producing a summary that 
included tweets from each day of the congress. The 
most successful tweeters were identified by the number 
of retweets received. An initial exploration of these data 
identified that there were commercial influencers—phar-
maceutical and biotechnology companies, device manu-
facturers and spam tweeters—posting throughout the 
congress and generating a considerable number of tweets 
and retweets. The most successful and prolific commer-
cial tweeters were excluded and the remaining tweets 
inspected. Further commercial tweeters were identified 
at successive stages of the analysis and their tweets were 
also excluded. Potential conflicts of interest (COIs) were 
surveyed and collected when users disclosed this informa-
tion on their profile. However, additional potential COIs 
were not cross- checked with other external sources, as 
we restricted the analysis to the content and the infor-
mation from Twitter. Some individuals posted mixed 
content during the congress, including posts mentioning 
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Figure 1 Final NodeXL map of #ESMO18 or #ESMO2018. Source: NodeXL map (14–24 October 2018). ESMO, European 
Society for Medical Oncology.
Table 1 Number of tweets extracted using NodeXL, 












19 October 1448 1453 99.7
20 October 1901 1921 99.0
21 October 1784 1795 99.4
22 October 1408 1433 98.3
23 October 559 584 95.7
All days 7100 7186 98.8
pharmaceutical companies and other tweets making clin-
ical/scientific points; where these individuals did not 
appear to have a link with commercial interests, their clin-
ical/scientific posts were retained in the analysis.
Results
The NodeXL map of interactions between tweeters, 
retweeters and mentioned Twitter accounts from the full 
extract is shown in figure 1.
After the initial difficulties extracting a complete 
dataset, the completeness of the final data was compared 
with the outputs of a simple Twitter search, displaying 
the publicly available tweet. Overall, NodeXL identified 
7100 tweets, and the Twitter search found 7186 tweets. 
NodeXL therefore extracted 98.8% of tweets (table 1).
After applying the inclusion and exclusion criteria 
shown in figure 2, 9.5% of #ESMO18/#ESMO2018 
tweeters were identified as commercial tweeters, posting 
15.7% of tweets and receiving 23.6% of the retweets.
After applying these exclusion criteria, the most popular 
non- commercial content was listed in a Wakelet summary 
of ‘top tweets’.6 This summary includes some content 
relating to congress organisation (eg, welcome and details 
about sessions) and some of the key learning points from 
plenary speakers and poster sessions. The tweets range 
from those capturing the comments of speakers to more 
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Figure 2 Algorithm and chart flow for selection of the tweets (source: NodeXL extract).
Table 2 Top tweeters by number of retweets received 19–23 October 2018 inclusive, after excluding commercial tweeters
Tweeter RTs received Tweets posted % of RTs received Cum % RTs received Followers
Myesmo 1060 107 6.5 6.5 27 962
MD 748 50 4.6 11.0 1309
MD 465 67 2.8 13.8 2835
MD 350 27 2.1 16.0 2646
MD 336 138 2.0 18.0 826
Thelancetoncol 311 42 1.9 19.9 19 778
Abcdiagnosis 308 147 1.9 21.8 13 808
MD 307 84 1.9 23.6 1155
Nejm 298 3 1.8 25.5 535 741
Cancernurseeu 253 63 1.5 27.0 2435
Vjoncology 219 83 1.3 28.3 1955
MD 218 25 1.3 29.7 4787
Medscapeonc 196 24 1.2 30.9 24 130
MD 184 25 1.1 32.0 3919
MD 183 13 1.1 33.1 1879
MD 183 18 1.1 34.2 1004
MD 176 14 1.1 35.3 2335
MD 171 35 1.0 36.3 3361
Gustaveroussy 167 34 1.0 37.3 10 856
Onclive 164 70 1.0 38.3 17 573
Source: NodeXL.
Cum, cumulative; MD, medical doctor; RT, retweet.
reflective posts, where individual posters add their own 
views.
The top 20 tweeters included in this analysis, after 
excluding commercial tweeters, are listed in table 2. The 
5983 tweets included in this analysis were posted by 1237 
tweeters, with 16 430 retweets.
Eighty per cent of the users delivering ‘non- commercial’ 
tweets (n=993/1237) had information on the location 
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Figure 3 Venn diagram showing tweeters, retweeters and mentioned Twitter accounts for #ESMO18/#ESMO2018 tweets 
(source: NodeXL (listed accounts were in the top five for that category, for the listed measures)). n=7630 accounts (source: 
NodeXL extract). Commercial tweeters are blanked out using asterisks. In order to protect anonymity, individual users have 
been shown as either MD or non- MD. MD, medical doctor; non- MD, non- medical tweeter; RT, retweet.
section of the profile, in terms of regions of the world; 
of them, for 95.9% (n=952), it was possible to identify 
also their country (online supplementary appendix 1). 
More than 90% of the users were registered in a Euro-
pean country (n=575), USA (n=260), Canada (n=26) and 
Australia (n=21) (online supplementary appendix 2).
Overall, 178 (14.4%) of the included tweeters received 
80% of retweets, while 373 (30.2%) of the included 
tweeters received no retweets. The official account of 
ESMO, @myesmo, ranked first for the retweets received, 
leading the information on the network. The most influ-
ential tweets were posted by two top oncology journals 
and oncology web channels and by the members of the 
ESMO faculty and ESMO committees.
Data on individual tweets, tweeters, Twitter accounts 
mentioned in tweets and retweeters are shown in figure 3, 
looking at included and excluded tweeters. Details of 
pharmaceutical companies and biotech investors have 
been blanked out in the figure, and details of individuals 
posting non- commercial posts have been anonymised.
Pharmaceutical and biotech tweeters were among the 
most prominent Twitter accounts by retweets received, 
mentions and/or retweets made. Further analysis, 
however, shows a more complex picture. As identi-
fied in figure 1, pharmaceutical company and biotech 
tweeters made up 9.5% of tweeters but posted a signif-
icant number of tweets (15.7%) and received an even 
higher proportion of retweets (23.6%). However, phar-
maceutical and biotech tweeters were substantially 
less likely to be mentioned by other tweeters. In total, 
there were 5241 mentions of 1342 Twitter accounts in 
#ESMO18/#ESMO2018 tweets; for pharmaceutical and 
biotech accounts, there were only 215 mentions (4.1% of 
the total) of 37 accounts (2.8% of the total).
Retweeters also differed for tweets excluded and 
included in the analysis. Of the 21 511 retweets made, 5081 
retweets were by the excluded group. NodeXL recorded 
details of the individual retweeters for 5071 of these 
retweets. All of the top 10 retweeters for the pharmaceu-
tical/biotech tweets (making up 21% of these retweets) 
were themselves pharmaceutical and/or biotech or anon-
ymous (n=3 had no details in their Twitter profile). In 
contrast, for the included tweets, of the 15 364 retweets 
with individual details, all of the top 10 retweeters (making 
up 13% of these retweets) were clinicians and/or profes-
sional organisations, with full details in their profile. One 
of the clinicians stated interest in ‘business’.
DIsCussIon
This study describes Twitter activity during the ESMO 
Congress 2018, a major international forum for sharing 
new research and updates in medical oncology. It intro-
duces new methods for describing and understanding the 
social media content and contributors at a conference 
of this size. The methodology mirrors that of systematic 
reviews of the scientific literature. The search term, inclu-
sion and exclusion criteria, completeness of data and 
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publication bias, validity of data and potential COIs were 
assessed, providing a conceptual framework of reporting 
social media activity at medical conferences.
One of the weaknesses of the study could be that the 
Twitter activity recorded relates specifically to tweets 
using the hashtags, not the subsequent replies, unless 
they also included the hashtag. Some of the tweets gener-
ated a large number of replies; for example, one prom-
inent tweet received 66 replies, only one of which used 
either hashtag.7 Extracting details of all related replies 
would not be feasible for a congress of this size, so the 
analysis has focused on tweets using the congress- related 
hashtags. While Twitter search results are available indef-
initely, with tweets available from the start of Twitter 
(2006), social network analysis has a limit of 9–10 days, 
and 18 000 tweets and/or retweets, which is sufficient for 
most medical meetings, sometimes combining extracts 
over several days as was the case here.
Social media have been shown to have a role in dissem-
inating findings at conferences8 and, more generally, in 
public events. Twitter has been proposed as the ideal 
ground for networking and developing discussions in 
global oncology, ensuring equal access to education for 
healthcare providers, including cancer care providers. 
Clinicians, scientists, patients and the general public rely 
on evidence- based information, shared safely and free of 
commercial influence. The role and potential benefit of 
information and communication technologies for health, 
including social network platforms, have been highlighted 
by the WHO as a way to enhance the education of the 
health workforce.9 For instance, according to the WHO 
EURO report ‘From Innovation to Implementation, 
eHealth in the WHO European Region’,10 ‘Healthcare 
social media can also be a source where relevant activities 
and discussions can enhance the continued professional 
development for nurses and other health professionals, 
as well as for patient education’. In fact, one study showed 
that non- profit organisations (NPOs) and community 
groups provide the highest rate of tweets about health 
literacy, among users of the social networking platform, 
highlighting the educational role of the key stakeholders 
operating under the umbrella of medical or scientific 
NPOs. This emphasises the responsibilities of scientific 
societies that provide clinical recommendations as well as 
NPOs advocating for patients’ care.11
Oncologists and other cancer healthcare providers, 
including cancer nurses, are increasingly joining social 
media platforms for professional purposes, actively 
participating and sharing case studies and reports.12 As 
a result, this provides a key opportunity to allow users to 
connect directly to experts in the field and enrich their 
knowledge. Furthermore, the use of a virtual interaction 
platform reduces issues related to hierarchy, allowing two- 
way information sharing from trainees to senior physi-
cians and professors and providing a novel e- mentorship 
platform.
However, commercial influencers are attempting to 
influence social media, biassing the dissemination of 
information. Our study demonstrates the heteroge-
neous nature of information during a major interna-
tional medical congress (ESMO Congress 2018), both for 
dissemination of new knowledge from key opinion leaders 
and as part of pharma marketing, with pharmaceutical/
biotech tweeters receiving almost a quarter of all retweets 
mainly generated from within the pharmaceutical and 
biotech community. Nevertheless, pharmaceutical/
biotech tweeters were much less likely to be mentioned in 
congress tweets (4.1% of tweets), suggesting less interest 
and potential influence on this network of clinical 
tweeters. While the Wakelet summary has been filtered 
to remove pharmaceutical companies and other commer-
cial tweeters, the view of the ESMO Congress 2018 from 
a simple Twitter search for the congress- related hashtags 
was heavily populated with commercial tweets. The view of 
tweets depends on Twitter settings, with popular content 
ranking highly in the ‘Top’ tab on Twitter. On this basis, 
it is likely that commercial tweeters achieved extensive 
visibility, with or without paying for advertising. Dele-
gates searching for the conference hashtag on personal 
computers or mobile devices may not realise that they are 
viewing and/or sharing commercial posts. Analysing the 
category of tweeter, as shown in figure 3, is therefore rele-
vant. This analysis provides insights into the people and 
organisations leading conversations in the congress venue 
and on social media, and their further dissemination.
Though there are important potential benefits in scien-
tific communication via Twitter, a number of caveats 
and potential adverse outcomes in its use have been 
identified.13
First, the diffusion of unpublished data has been argued 
to reduce the appeal for publication of high- impact jour-
nals.14 However, tweeting can also be part of an effective 
communication strategy including ‘teaser’ posts that 
increase visibility and visual abstracts that translate find-
ings in a more digestible way.
Second, the excitement related to the disclosure of 
long- awaited data could generate unrealistic expecta-
tions. Oncology is, arguably, particularly susceptible to 
this phenomenon with ‘miracle cure’ claims commonly 
posted in the lay press. For instance, the hype for inter-
esting exploratory results and the promotion of results 
demonstrating narrow benefit for innovative cancer inter-
ventions by pharmaceutical companies could outshine 
the real magnitude of benefit in clinical practice, poten-
tially providing a misleading message for the community, 
including health providers and patient advocacy groups.
Finally, Twitter does not request the disclosure of 
declarations of interest for the subscribers, unless repre-
senting a company. As a result, it has been argued that 
pharmaceutical companies can engage health providers 
to hype drugs, strategically promoting some medicines, 
as well as stressing the positive achievements of clinical 
trials. In a report by Kaestner et al, almost 80% of haema-
tologists–oncologists on Twitter had some COIs with 
companies.15 16 Interestingly, 80% among the most active 
haematologists on Twitter mentioned at least one drug 
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from a company for which a financial COI was disclosed 
elsewhere. However, 1.3% reported such conflict on 
their Twitter profile: of the total drug mentions, more 
than 50% regarded conflicted drugs. The message is 
that pharmaceutical companies can directly or indirectly 
highlight and hype their own business, providing ambig-
uous messages for patients and providers on unregulated 
but widely used social network channels; an example of 
polýtropos pharma influencing strategies. For instance, in 
our study (figure 2), a substantial proportion of tweets 
belonged to pharmaceutical companies, raising concerns 
from medical tweeters, before filtering and exclusions 
were applied. It is therefore reassuring that 90% of 
tweeting was not commercially related, demonstrating 
the level of interest in the ESMO 2018 Congress by scien-
tists and clinicians from within the congress venue and 
beyond. Wading through commercial posts to find these 
non- commercial posts was, however, dispiriting and was 
noted by participants at the congress and on social media.
This analysis shows the extensive tweeting about a 
major international oncology congress. Understanding 
the way that information is disseminated on social media 
is important, particularly considering effectiveness, access 
and cost of treatment. Professionals, pharmaceutical 
companies and biotech investors all tweeted about the 
congress. A more recent cancer conference in the UK 
(#NCRI2018) did not identify pharmaceutical or biotech 
tweeters among its top influencers in a NodeXL extract.17 
Analysis of previous conferences on other topics, 
including infectious diseases and cardiology, has not illus-
trated a similar level of commercial influence.18–20
Once the commercial posts were excluded from the 
#ESMO18/#ESMO2018 analysis, we were able to extract 
clinical and scientific information less likely to present 
marketing- related bias, even though the volume of tweets 
initially seemed overwhelming. The Wakelet summary6 
shows the text and any images and lets the viewer explore 
further content (eg, replies). The summary captures posts 
from plenary, parallel and poster sessions, with coverage 
of the congress that would have been unachievable for 
individual delegates. The summary also potentially has 
value beyond this current analysis. Materials presented 
at conferences may not ultimately be published in peer 
reviewed high- impact journals. We know that trials 
presenting positive findings may be favoured over studies 
showing no effect, as enthusiasm for novelty gener-
ally prevails, leading to publication bias. Reading the 
congress programme, viewing congress- related tweets 
and searching trial registries could potentially allow the 
identification of unpublished research and preliminary 
findings from such research. This could overcome the 
often described publication bias of scientific publications.
It would be difficult, if not impossible, to regulate the 
dissemination of health- related information on social 
media as it is currently organised. Nonetheless, the find-
ings of this analysis should make conference organisers 
and all the relevant stakeholders consider options for 
managing such content in the future, either through 
voluntary codes, a separate hashtag for pharmaceutical 
companies and biotech investors to use (eg, #pharma or 
#biotech), or showing tweeters how to use the Twitter 
search function to exclude specific tweeters. Adding a 
‘-’ symbol in front of a search term excludes that term 
from the search, so individual tweeters or tweets using 
specific hashtags can be easily removed from searches 
(using ‘-from:’ in front of an account name in a Twitter 
search excludes tweets from that user). Such approaches 
can equally apply to individuals and campaigns of public 
health interest, such as those tweeting about vaccination, 
tobacco control and infectious disease pandemics.
Social media have their place in delivering, learning and 
sharing data around medical oncology. However, just as 
with traditional reporting and research, we need to critically 
appraise content and consider COIs before deciding what 
to read and believe. The observation that pharmaceutical 
companies and investors made such a concerted effort to 
influence this medical oncology congress should raise ques-
tions about similar influence on wider tweeting and future 
conferences. On the other side, healthcare providers and 
other key stakeholders can play critical roles in the strate-
gies of marketing of tradable goods, even if not directly on 
behalf of companies, so that it becomes essential to tackle 
the broader environment that can generate COI. In this, 
policies and recommendations from international organ-
isations are called for to regulate commercial interests in 
conference tweeting and more generally.
A quality check for Twitter has not been established so 
far: a reliable fingerprint to favour the diffusion of high- 
quality evidence to inform appropriate media communi-
cations is currently lacking. Manipulation for profit can 
still occur, giving false hopes to patients with clear poten-
tial for harm from inappropriate and biassed messages.
We have quantified the level of commercial tweeting and 
suggest a call to action, to develop a framework for safe 
and high- quality tweeting during future ESMO congresses, 
leaving no stakeholder, patient or user misinformed. Again, 
it is everybody’s commitment for the best care.
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